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Abstract
Background and Aims The inflammatory bowel diseases (IBD) are particularly common among the Ashkenazi Jewish (AJ) 
population. Population-specific estimates of familial risk are important for counseling; however, relatively small cohorts of 
AJ IBD patients have been analyzed for familial risk to date. This study aimed to recruit a new cohort of AJ IBD patients, 
mainly from the UK, to determine the familial occurrence of disease.
Methods A total of 864 AJ IBD patients were recruited through advertisements, hospital clinics, and primary care. Par-
ticipants were interviewed about their Jewish ancestry, disease phenotype, age of diagnosis, and family history of disease. 
Case notes were reviewed.
Results The 864 probands comprised 506 sporadic and 358 familial cases, the latter with a total of 625 affected relatives. 
Of the UK cases, 40% had a positive family history with 25% having at least one affected first-degree relative. These per-
centages were lower among those recruited through hospital clinics and primary care (33% for all relatives and 22% among 
first-degree relatives). Examining all probands, the relative risk of IBD for offspring, siblings, and parents was 10.5, 7.4, and 
4, respectively. Age of diagnosis was significantly lower in familial versus sporadic patients with Crohn’s disease.
Conclusions This study reports familial risk estimates for a significant proportion of the AJ IBD population in the UK. The 
high rate of a positive family history in this cohort may reflect the greater genetic burden for IBD among AJs. These data 
are of value in predicting the likelihood of future recurrence of IBD in AJ families.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two major forms of inflammatory bowel disease (IBD), a 
heterogeneous group of chronic and debilitating disorders 
characterized by inflammation of the gastrointestinal tract [1, 
2]. IBD is a global disease, the prevalence and incidence of 
which have significantly increased since the 1950s, particu-
larly over the last few decades in developed countries [3]. 
Recent estimates suggest that the prevalence of IBD is over 
0.3% in North America, Australia, and many countries in 
Western Europe. IBD is also emerging in newly industrial-
ized countries as they adopt a Westernized diet and lifestyle 
[4].
The etiology of IBD is thought to involve an aberrant 
immune response to commensal microflora in genetically 
susceptible individuals exposed to environmental risk fac-
tors [5, 6]. Epidemiological studies have consistently shown 
an increased prevalence of IBD among first-degree relatives 
(FDRs) of patients with CD and UC; this familial cluster-
ing, in addition to the increased incidence of disease among 
monozygotic (MZ) twins, provided the initial evidence of 
a genetic predisposition to IBD [7, 8]. Concordance in MZ 
twins is > 30% for CD and 16% for UC, while only 4% for 
both in dizygotic twins [9, 10]. A positive family history is 
the strongest risk factor for developing IBD; FDRs of an 
IBD patient have a 10–15 times greater risk of the disease 
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compared with the general population [11, 12]. If both par-
ents have IBD, the lifetime risk to their offspring is thought 
to be over 30% [13, 14].
The Jewish population comprises three main groups: Ash-
kenazim, Sephardim, and Mizrahim. The Ashkenazi Jewish 
(AJ) population is a founder population that comprises the 
majority of contemporary world Jewry. From the twelfth 
century, AJs lived in Central and Eastern Europe, moving 
primarily to the USA, Western Europe, and Israel in the late 
nineteenth and early to mid-twentieth centuries [15]. The 
AJ population was subjected to repeated bottlenecks and has 
maintained its genetic isolation through endogamy, practiced 
for religious and cultural reasons. This genetic isolation is 
evidenced by the high prevalence of founder mutations [16] 
corresponding to over 100 autosomal recessive disorders 
[17] as well as a high frequency of risk variants for com-
mon diseases such as breast and ovarian cancer, Parkinson’s 
disease, and IBD [18].
IBD is particularly common among the AJ population 
as demonstrated in epidemiological studies in disparate 
geographic locations since the 1960s [19–26]. The latest 
published data suggest an approximately fourfold increased 
risk of IBD among AJs [27]. There are no recent published 
epidemiological studies assessing the prevalence of IBD in 
the contemporary AJ population. Using an IBD prevalence 
of 0.3% [4], a fourfold increase among AJs yields an esti-
mated prevalence of 1.2%. Previous studies reporting famil-
ial empirical risk estimates for IBD in the AJ population 
have been undertaken over 25 years ago using modest cohort 
sizes [26, 28].
The AJ population in the UK is thought to represent about 
95% of the total UK Jewish population, which an analysis of 
the 2011 national census enumerated as 271,259 individuals 
[29]. The contemporary UK Jewish population is estimated 
to display a relatively high degree of endogamy at 74% [30]. 
Using an AJ IBD prevalence of 1.2%, there are an estimated 
3100 AJ IBD cases in the UK.
The aim of this study was to recruit a new cohort of AJ 
IBD patients and their families, primarily from the UK, for 
epidemiological and genetic investigations [31]. Using 864 
AJ IBD-affected individuals, up-to-date estimates of the pat-
tern of familial disease and the risk to relatives are provided. 
Such data are relevant for genetic counseling.
Methods
Ethics
Ethical and research governance approval was provided by 
The National Research Ethics Service London Surrey Bor-
ders Committee (10/H0906/115) and the University College 
London Research Ethics Committee (6054/001). Informed 
consent was obtained from all participants.
Recruitment
Individuals with IBD were recruited through advertisements 
in Jewish press, predominantly in the UK but also in Israel 
and the USA, and via referrals from specialist IBD clinics 
and primary care (UK only). Recruitment was undertaken 
from 2013 to 2017. Participants were interviewed by tel-
ephone to ascertain their Jewish ancestry, IBD phenotype, 
age of diagnosis, and family history of IBD in both FDRs 
and distant relatives. Only individuals of self-reported AJ 
ancestry were included; those with Sephardi, Mizrahi, or 
mixed ancestry were excluded. IBD cases were considered 
to have “sporadic” IBD if there were no known relatives with 
the disease. They were considered to have “familial” disease 
if a first, second, or more distant relative was reported to 
have a diagnosis of CD or UC. The diagnosis of IBD in 
probands (index cases) and their relatives was evaluated by 
asking them detailed questions about their diagnosis, clinical 
course, and treatment. Through the probands, the majority 
(66%) of their affected relatives were subsequently recruited 
from the UK and multiple countries worldwide including 
Australia, Belgium, Canada, France, Gibraltar, Israel, Neth-
erlands, Norway, Portugal, South Africa, Switzerland, and 
the USA. Where possible a written confirmation of each 
affected individual’s diagnosis was obtained from his or her 
doctor. Sporadic and familial IBD cases were compared for 
IBD phenotype and age of diagnosis. Familial risk estimates 
were calculated. The ages of diagnosis in parent–offspring 
pairs was examined. Saliva samples were collected for 
genetic investigations.
Statistics
2 × 2 comparisons were made using Fisher’s exact test (two-
tailed). Multi-group comparisons for continuously distrib-
uted data were made using Tukey’s honest significant dif-
ference test. Single-group comparisons for continuously 
distributed data were made using Wilcoxon signed-rank test. 
Data analysis was performed in R.
Results
Participants
A total of 864 AJ index cases with IBD were recruited. Of 
these, 506 individuals had no family history of IBD (spo-
radic) and 358 reported one or more affected relative(s) 
(familial). In the families, there were a total of 625 addi-
tional affected relatives (301 FDRs and 324 more distant 
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relatives); information was directly obtained from 411 of 
these. Of the total 1489 AJ IBD individuals in the cohort, 
1261 (85%) were currently resident in the UK. Assuming a 
1.2% prevalence of IBD in AJs, the cohort represents over 
40% of the total predicted UK AJ IBD population.
Distribution of Disease and Family History
The percentage of probands with a positive family history 
of IBD in any relative was 41% (Table 1). The number of 
probands with a FDR with IBD was 231 (27%). The percent-
age of probands in the UK with a positive family history 
in any relative was significantly greater when the proband 
was recruited through advertising (44%) than through hos-
pital clinics and primary care (33%) (Fisher’s exact test 
p = 0.004) but not in FDRs only (p = 0.13). The percentage 
of probands with a positive family history in any relative 
and among FDRs only was significantly greater among 
probands recruited internationally (p = 0.002 and p = 0.003, 
respectively).
Table 2 shows the distribution of all 1489 affected indi-
viduals by type of IBD in familial and sporadic cases; a 
greater number of affected individuals had CD than UC in 
both the familial and sporadic groups. Of the 864 probands, 
528 (61%) had CD and 319 (37%) had UC. The remaining 17 
(2%) had either a clinically indeterminate phenotype (IBD 
unclassified) or their subtype was unknown.
A greater proportion of CD probands had an affected 
FDR (27%) than of UC probands (20%), p = 0.03. There 
was no significant difference in any positive family history 
among those with CD (43%) versus UC (41%), p = 0.62.
While affected relatives of a proband may develop either 
form of IBD, the greatest risk to a relative was for the con-
cordant type, particularly for a CD proband (examining 
FDRs: 83% for CD versus 62% for UC, p = 0.0007). Table 3 
shows the distribution of concordant and discordant FDRs 
of these probands.
The distribution of the total number of ascertained 
familial affected individuals in each of the 358 multiplex 
Table 1  Family history of IBD in all relatives and in first-degree 
relatives (FDRs) only of IBD probands, according to the method of 
recruitment
Recruitment method IBD probands Positive family history
All FDRs only
Advertisements (UK) 529 231 (44%) 144 (27%)
Hospitals, primary care 
(UK)
276 91 (33%) 61 (22%)
Total (UK) 805 322 (40%) 205 (25%)
International 59 36 (61%) 26 (44%)
Total (overall) 864 358 (41%) 231 (27%)
Table 2  Distribution of familial and sporadic patients by inflamma-
tory bowel disease subtype in probands and the entire cohort
CD Crohn’s disease, UC ulcerative colitis, IBDU inflammatory bowel 
disease unclassified/unknown
Probands only (%) All (%)
All IBD
 CD 528 (61%) 885 (59%)
 UC 319 (37%) 532 (36%)
 IBDU 17 (2%) 72 (4%)
 Total 864 1489
Familial IBD
 CD 225 (63%) 582 (59%)
 UC 130 (36%) 343 (35%)
 IBDU 3 (1%) 58 (6%)
 Total 358 983
Sporadic IBD
 CD 303 (60%)
 UC 189 (37%)
 IBDU 14 (3%)
 Total 506
Table 3  Distribution of all concordant and discordant affected FDRs 
of 209 CD and UC probands
Concordant phenotypes are indicated by italics
Number of familial 
probands with ≥ 1 
affected FDR by phe-
notype
Total number of affected FDRs by phe-
notype
CD UC Total
CD 144 161 (83%) 34 (17%) 195
UC 65 29 (38%) 48 (62%) 77
Total 209 190 82 272
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Fig. 1  Distribution of the number of ascertained families by number 
of affected relatives (all and first-degree relatives only separately)
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families is shown in Fig. 1, separately for all affected rela-
tives and for affected FDRs only. There were 24 families 
with five or more affected individuals. There were 146 CD 
or UC probands with affected relatives none of whom were 
FDRs. In at least 10 families, the disease was present in two 
or more unrelated branches of the family.
IBD in Spouses
Eight probands had an affected spouse; five of the couples 
(62.5%) were concordant for IBD phenotype: four for CD 
and one for UC. The mean age of disease diagnosis was 23.9 
in the first affected spouse and 24.8 in the second affected 
spouse. Only one of the 25 offspring of these eight couples 
was affected (diagnosed at 15 years of age); however, 18 of 
the remaining 24 offspring were under 20 years old at the 
time of ascertainment, and some of them may yet manifest 
IBD.
Relative Risks in FDRs
Details of the number and affected status of all FDRs were 
provided by the majority of the 864 probands. In order to 
prevent an overestimation of the relative risk due to a poten-
tial biased inclusion of affected versus unaffected relatives, 
probands were excluded when the number and phenotype of 
all FDRs were incomplete. For two probands, there was no 
information regarding the parents. The frequency with which 
probands were excluded due to incomplete FDR informa-
tion was greater in sporadic versus familial cases for both 
offspring and siblings (30.8% vs. 11.2% and 36.2% vs. 9.2%, 
respectively). Six hundred and sixty-eight probands had 738 
offspring, of whom 93 (13%) were affected. Using the esti-
mated prevalence of IBD in the AJ population of 1.2% (as 
above), the relative risk for offspring was 10.5. The relative 
risks for sibling and parents were 7.4 and 4, respectively. 
The likelihood of having a child with IBD was slightly 
greater if the proband had CD than if they had UC (14% vs. 
9% for offspring), although not quite reaching statistical sig-
nificance (p = 0.06). Table 4 summarizes these data, showing 
the percentage of offspring, siblings, and parents affected 
and the respective relative risks, for all IBD, for CD, and for 
UC probands. Relative risks or percentages of affected FDRs 
from other studies are provided for comparison. Examining 
only familial cases for IBD, the relative risks for offspring, 
siblings, and parents were 17.0, 12.9, and 9.7, respectively 
(data not shown).
Age of Diagnosis of IBD in Cases
The age of diagnosis differed significantly between CD and 
UC and familial and sporadic cases, as shown in Fig. 2. 
The data demonstrated a positive skew. The lowest age 
of diagnosis was observed in CD familial cases (median 
20 years), and the greatest age of diagnosis was observed in 
UC sporadic cases (median 28.5 years). CD familial cases 
were statistically significantly younger at diagnosis than 
CD sporadic cases (p = 1.4 × 10−5) and UC familial cases 
(p = 2.5 × 10−6). The age at diagnosis of sporadic CD and 
UC cases, and UC familial and sporadic cases was not sta-
tistically different.
Parent and Offspring Ages of Diagnosis
Of the 124 parent–offspring duos from whom ages of diag-
nosis were available, 79% of the children were diagnosed at 
a younger age than the affected parent, with a median age 
difference of 13 years (p = 3 × 10−14). This reduced to eight 
years but remained statistically significant (p = 1 × 10−6) 
when only parents diagnosed aged ≤ 40 years at the time of 
analysis were considered, in order to prevent an inadequate 
follow-up time bias of the offspring compared to the parents 
[32, 33].
Discussion
This study reports updated familial risk estimates for the 
AJ IBD population utilizing a large newly recruited cohort, 
predominantly from the UK. Assuming a 1.2% prevalence 
of IBD in AJs, the 1261 AJ IBD individuals from the UK in 
this cohort represent a significant proportion (over 40%) of 
the estimated total UK AJ IBD population. The resulting risk 
estimates may be of benefit for genetic counseling. We report 
a 40% familial incidence of IBD in the UK with 25.5% of 
individuals with IBD having at least one first-degree relative 
with IBD. This is somewhat high in comparison with previ-
ous studies in non-AJ populations and is partly driven by the 
high number of familial cases who responded to our adver-
tisements. Limiting the familial incidence estimates to cases 
recruited through hospitals and clinics (unbiased to family 
history status), we report a 33% familial incidence of IBD 
with 22.1% of individuals having at least one affected FDR. 
This matches well with results from a large recent study in 
the USA of 2136 patients with IBD (of variable ethnicity) 
which reported 32% familial incidence of IBD with 17% 
having at least one affected first-degree relative [34]. In a 
review of studies published up to 2002 [12], the occurrence 
of a positive family history of IBD varied from 5 to 16% 
in CD and 8 to 14% in UC. Large multigenerational stud-
ies from Sweden and Holland reported first-degree familial 
incidence of IBD in 6–12% [35, 36].
The rate of familial IBD observed in our cohort is 
greater than that of previous studies examining the AJ 
population (Table 5). However, it is important to note that 
there are challenges when comparing different studies 
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given differing study designs and ascertainment method-
ologies. Defining familial IBD varies with some studies 
reporting family history in FDRs only and others includ-
ing more distantly related relatives (e.g., second and third 
degree), as has been done in the present study. Some stud-
ies assign the risk of CD or UC [37–40], while others 
assign a risk to all types of IBD together [26, 28].
Accurate empirical risk estimates are one of the most 
important tools for genetic counselors in supporting fami-
lies and explaining complex diseases such as IBD [41] 
where the collective effect of multiple genetic loci has not 
been fully determined. The empirical risk estimates for 
siblings are more reliable compared to those for offspring 
or parents because probands and their siblings live tempo-
rally, removing generational bias [26]. Parents consistently 
have the lowest risk estimates, perhaps due to improved 
diagnosis and consistent with the increasing incidence of 
Table 4  Calculation of relative 
risk of IBD in first-degree 
relatives (FDRs) of patients 
with IBD, CD and UC
The number of probands from whom FDR information was available is in brackets. p: assumed prevalence 
of IBD in AJ population, 1.2%
Relative type
Offspring Siblings Parents
All probands (n = 864; 506 sporadic, 358 familial)
 Total affected and unaffected, t 738 (668) 1407 (648) 1724 (862)
 Number affected, m 93 (318) 125 (325) 83 (356)
 Unaffected FDRs of sporadic probands 281 (350) 600 (323) 1012 (506)
 Unaffected FDRs of familial probands 364 (318) 682 (325) 629 (356)
 Percentage affected in all families, f = m/t 13% 9% 5%
 Relative risk in all families, r = f/p 10.5 7.4 4
All CD probands (n = 528; 303 sporadic, 225 familial)
 Total affected and unaffected, t 478 (400) 962 (390) 1054 (527)
 Number affected, m 69 (196) 90 (204) 51 (224)
 Percentage affected in all families, f = m/t 14% 9% 5%
 Relative risk in all families, r = f/p 12 7.8 4
All UC probands (n = 319; 189 sporadic, 130 familial)
 Total affected and unaffected, t 246 (257) 426 (248) 636 (318)
 Number affected, m 23 (119) 34 (118) 31 (129)
 Percentage affected in all families, f = m/t 9% 8% 5%
 Relative risk in all families, r = f/p 7.8 6.7 4.1
Percentages of affected FDRs in other AJ studies
Roth et al. [28]
 Uncorrected prevalence, n = 154 3% 5% 3%
 Age-corrected prevalence, n = 154 9% 9% 4%
Yang et al. [26]
 Uncorrected prevalence in CD, n = 134 2% 8% 3%
 Age-corrected prevalence in CD, n = 134 7% 17% 4%
 Uncorrected prevalence in UC, n = 157 2% 2% 3%
 Age-corrected prevalence in UC, n = 157 7% 5% 4%
Satsangi et al. [42]
 Relative risk of IBD, n = 433 24.7 12.5 4.4
CD Familial CD Sporadic UC Familial UC Sporadic
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Fig. 2  Box and whisker plots showing the distribution of age of diag-
nosis in Crohn’s disease (CD) and ulcerative colitis (UC) in familial 
and sporadic cases separately. *** p < 2 × 10−5, ns nonsignificant
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IBD in recent years. The relative risk for parents in our 
study was consistent with the literature [28, 42].
It has previously been observed that familial IBD cases 
tend to have an earlier age of onset compared to sporadic 
cases [34, 38, 43] although not all studies agree [44]. We 
observed this in our cohort for CD but not UC. Recent stud-
ies demonstrate that positive family history is also associated 
with complicated CD behavior and the need for IBD-related 
surgery [34, 45, 46], indicating the importance of establish-
ing a family history for clinical and treatment prognosti-
cation. Information regarding disease severity was not col-
lected in this study.
Our observation of a generational difference in the age 
of diagnosis in parent–offspring duos is consistent with pre-
vious studies in IBD [47–49]. Genetic anticipation as an 
explanation for this finding has been shown to be unlikely, 
and it is thought instead that ascertainment biases, especially 
inadequate follow-up time, are responsible [33, 50, 51].
Limitations of this study include potential biases and 
inconsistencies introduced in the recruitment process. 
The majority of affected individuals and their respective 
families were recruited through advertisements in the Jew-
ish press; the second largest recruitment source was IBD 
clinics from five London hospitals in areas with a high 
Jewish population. As teaching hospitals, the latter are 
more likely to attract patients with severe disease, more 
common in familial cases [34]. Two potential issues with 
recruitment by advertisements are worth noting. Firstly, 
in contrast to the IBD clinics, participants responding 
to the advertisements self-reported their phenotypes. In 
the majority of cases (56%), the phenotype was indepen-
dently verified by the patient’s clinician but this was not 
always possible. Self-reported IBD status has previously 
been found to be highly accurate [52, 53]. The other issue 
with recruitment by advertisement relates to the potential 
bias toward familial IBD. Since the aim of this study was 
also to identify multiplex families for genetic analysis, 
the advertisement particularly encouraged participation 
of such cases. This is evident in the data in which the 
percentage of probands with a family history was greater 
among those recruited by advertisement. It is also possi-
ble that there was more of an incentive to participate in a 
genetic study for familial cases.
Furthermore, we have also relied on probands self-
reporting a positive or negative family history. The reli-
ability of this has not been previously studied for IBD, 
although it has been demonstrated to be accurate for some 
cancers [54, 55]. Lack of contact with relatives may cause 
underreporting of IBD in a family, while ignorance of 
diagnosis may cause over-reporting.
The lifetime risk of IBD in the probands’ relatives has 
not been adjusted for age. Since many of the relatives are 
young, they may still develop IBD. The relative risks cal-
culated may thus be underestimated, although the afore-
mentioned biases may counteract this.
This study characterizes a newly recruited AJ IBD pop-
ulation and examines the distribution of family history in 
detail. The relatively high rate of a positive family history 
in this cohort may reflect the greater genetic burden for 
IBD among AJs [56, 57]. Such data and the relative risk 
estimates are of value in predicting the likelihood of future 
recurrence of IBD in a family.
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Table 5  Comparison between 
the present cohort and previous 
studies on the occurrence of 
familial IBD in AJs, showing 
occurrence of any affected 
relatives and affected first-
degree relatives in probands 
with IBD
a The studies by Ben-Horin et  al. examined the Israeli Jewish population; approximately 40% of the 
probands were Ashkenazi
Study Phenotype Number of AJ 
probands
Any family 
history
FDR with IBD
Roth et al. [28] IBD 154 23.4% 17.6%
Zlotogora et al. [37] CD 157 NA 6.6%
Yang et al. [26] IBD 291 24.3% NA
Zhou et al. [38] CD 481 22.8% NA
Ben-Horin et al. [39]a CD 181 NA 16%
Ben-Horin et al. [39]a UC 168 NA 14%
This study—total IBD 864 41% 25%
This study—UK IBD 805 40% 26%
This study—UK CD 484 41% 28%
This study—UK UC 304 41% 22%
This study—UK Hospitals and 
primary care only
IBD 276 33% 22%
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